Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for PN-Induced Hepatic Injury
NCT01325584Phase 2Terminated
- Sponsor
- City of Hope Chicago
- Start
- Oct 2012
- Primary completion
- Dec 2016
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD), sponsored by City of Hope Chicago. Primary endpoints: Maximum Conjugated Bilirubin at 4 weeks, Average Change in Alkaline Phosphatase at 4 weeks and 3 more. Started Oct 2012; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT01325584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01325584.